Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Real-time Estimate Tradegate
Other stock markets
 01:13:48 2024-06-03 pm EDT 		5-day change 1st Jan Change
17.25 EUR -8.00% Intraday chart for Frazier Lifesciences Acquisition Corporation -0.37% +67.86%
May. 21 NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings CI
May. 16 Transcript : NewAmsterdam Pharma Company N.V. - Special Call

Evolution of the average Target Price on Frazier Lifesciences Acquisition Corporation

Price target over the last 5 years

History of analyst recommendation changes

144b0d.5SozOdEePIT_J5XWCRQPAlC1HHBpY5Zqy-HkfM_yq5s.gGJUb4ZMXfCUCq2RSEA7YwjPayNcB8MamLmDC4LDmPyQG2RIgWR63b5grQ~ceb640935749c54168ec599a3277d38e

Analyst Recommendations on Frazier Lifesciences Acquisition Corporation

TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target MT
William Blair Starts NewAmsterdam Pharma at Outperform MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.29 EUR
Average target price
32.12 EUR
Spread / Average Target
+85.76%
High Price Target
41.37 EUR
Spread / Highest target
+139.30%
Low Price Target
26.81 EUR
Spread / Lowest Target
+55.08%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Frazier Lifesciences Acquisition Corporation

TD Cowen
Scotiabank
RBC Capital Markets
Guggenheim
Credit Suisse
SVB Securities LLC
Jefferies & Co.
William Blair & Co.

Ratings for Frazier Lifesciences Acquisition Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. Consensus Frazier Lifesciences Acquisition Corporation